ASH 2014 | Novel biological therapies for managing non-Hodgkin lymphoma

Martin Dreyling

Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel biological therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Share this video  
Similar topics